Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day by Shemesh, Gabi et al.
© 2012 Shemesh et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2012:6 283–287
Clinical Ophthalmology
Intraocular pressure reduction of fixed 
combination timolol maleate 0.5%  
and dorzolamide 2% (Cosopt) administered  
three times a day
Gabi Shemesh*
Elad Moisseiev*
Moshe Lazar
Shimon Kurtz
Department of Ophthalmology, 
Tel Aviv Sourasky Medical Center,  
Tel Aviv, Israel; Affiliated to the 
Sackler Faculty of Medicine,  
Tel Aviv University, Tel Aviv, Israel
*The first two authors contributed 
equally
Correspondence: Elad Moisseiev 
Department of Ophthalmology, Tel Aviv 
Sourasky Medical Center, Weitzman 6 St, 
Tel Aviv, 64239, Israel 
Tel +972 3 6973408 
Fax +972 3 6973870 
Email elad_moi@netvision.net.il
Purpose: To evaluate the safety and efficacy in intraocular pressure (IOP) reduction of 
  increasing Cosopt dosage from twice to three times a day.
Methods: The study included patients with primary open-angle glaucoma or ocular h  ypertension. 
After a washout period, IOP was measured at baseline, after 4 weeks of treatment with   Cosopt 
twice a day, and after another 4 weeks of treatment with Cosopt three times a day. Blood   pressure, 
heart rate, and oxygen saturation levels were also recorded.
Results: Twenty-nine eyes of 29 patients were included. Increasing Cosopt dosage resulted 
in a statistically significant (P , 0.001) additional reduction in IOP of 2.2 ± 1.58 mmHg 
(10.69% ± 7.49% of the baseline IOP values). There were no local or systemic adverse effects.
Conclusion: Treatment with Cosopt three times a day was more effective in reducing IOP than 
twice a day, with no effect on safety.
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Introduction
Primary open-angle glaucoma (POAG) is a chronic progressive disease, characterized 
by painless intraocular pressure (IOP) elevation, optic nerve damage, and visual field 
loss.1 POAG is the most common adult-onset type of glaucoma in the western world, 
and incidence increases with age.2 It is one of the most common causes of chronic 
visual impairment3 and the second leading cause of blindness in the world.4
Large scale clinical studies have demonstrated the importance of early IOP 
reduction in order to prevent optic nerve damage and visual loss.5–8 Specifically, the 
Early Manifest Glaucoma Trial has shown that every 1 mmHg reduction in IOP is 
important, and is associated with approximately 10% reduction in the risk of disease 
progression.8
First-line treatment typically consists of monotherapy with a single agent, and if 
the IOP reduction is insufficient treatment is switched to an alternative monotherapy or 
combination with a second agent.9 In patients requiring treatment with more than one 
agent, combination therapy is usually preferred since it is associated with increased 
compliance.10,11 However, it has been shown that in reality, combination therapy is 
often administered as first-line therapy for patients diagnosed with POAG or ocular 
hypertension (OHT).11,12
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A common combination treatment for glaucoma is 
  Cosopt® (Merck & Co, Inc, Whitehouse Station, NJ), 
which is a fixed single dose combination of maleate timolol 
0.5% (a nonselective beta-blocker) and dorzolamide 2.0%   
(a carbonic anhydrase inhibitor). Combination therapy with 
Cosopt has been consistently proven to be more effective 
in IOP reduction than monotherapy with either timolol or 
dorzolamide.13–15 It has also been demonstrated that treat-
ment with Cosopt is as safe and effective as concomitant 
treatment with timolol and dorzolamide.16–18 Treatment with 
Cosopt has been shown in various studies to decrease IOP 
by 10.6%–40%, with an average of 25%–30% reduction of 
IOP.11,13,14,16,19–24
All studies involving Cosopt included twice-daily 
administration. The recommended administration of its 
components is twice a day for timolol and three times a day 
for dorzolamide.16,17 A review of the literature revealed no 
study in which Cosopt was administered three times a day. 
The purpose of this study was to assess the safety and efficacy 
in IOP reduction of increasing Cosopt dosage from twice to 
three times a day.
Methods
Twenty-nine patients with POAG or OHT were included 
in this study. All patients were 18 years or older, and were 
diagnosed with POAG or OHT by a glaucoma specialist 
after undergoing detailed ophthalmologic examination 
including evaluation of glaucomatous optic disc damage and 
gonioscopy, IOP measurements by applanation tonometry, 
and automated perimetry. Patients with advanced glaucoma 
(mean deviation lower than −12 dB or presence of central 
scotoma) were not included.
Exclusion criteria included closed-angle glaucoma or 
secondary open-angle glaucoma, such as pseudoexfolia-
tion or pigment-dispersion syndrome. Also excluded were 
patients receiving systemic treatment with beta-blockers or 
carbonic anhydrase inhibitors for any reason, and patients 
with systemic conditions that may be adversely affected 
by timolol or dorzolamide, such as asthma, hypotension, 
bradycardia, cardiac arrhythmia, impaired kidney function, 
or impaired hepatic function. Patients who had previously 
undergone surgery or laser treatment to reduce IOP were also 
excluded. All patients had visual acuity of 20/80 or better. 
Only one eye of each patient was included in the study. If 
both eyes of a patient met the inclusion criteria, the left eye 
was routinely chosen arbitrarily.
All patients were previously treated only by either dor-
zolamide or timolol, and treatment was switched to Cosopt 
twice a day for a washout period of 4 weeks. Patients were 
then followed for another 4 weeks and then the dosage was 
increased to three times a day for another 4 weeks.
IOP was measured in all patients at baseline, after 
4 weeks of treatment with Cosopt twice a day, and after 
another 4 weeks of treatment with Cosopt three times   
a day. Baseline measurements were made after a 4 week 
washout period with Cosopt twice a day, to eliminate any 
effect of p  revious treatment. All measurements were made 
by   Goldmann applanation tonometry, and were performed 
by a single   ophthalmologist. All measurements were taken 
between 8–10 am, prior to instillation of the morning drop 
of Cosopt.
At each time point heart rate, blood pressure, and blood 
oxygen saturation levels were measured. Heart rate and 
blood pressure were measured by an automatic device and 
oxygen saturation was measured by a pulse oxymeter. All 
measurements were made by the same physician at the time 
of IOP measurement.
The study protocol was reviewed and approved by the 
Institutional Review Board, and a written informed consent 
was obtained from all participants.
Descriptive statistics including the mean and standard 
deviation (SD) were produced for all continuous study 
variables. The statistical significance of the changes in 
IOP, systolic and diastolic blood pressure, heart rate, and 
oxygen saturation levels between time points was assessed 
by   Student’s t-test for paired observations. The statistical 
significance level was set at 0.05. Data were analyzed using 
SPSS for Windows (version 17.0; SPSS Inc, Chicago, IL).
Results
Twenty-nine eyes of 29 patients were included in the 
study. Patients included 17 men (58.7%) and 12 women 
(41.3%), with a mean age of 71.1 years ± 7.9 (SD) (range 
59–85 years).
At baseline, mean IOP levels were 21.11 ± 3.14 mmHg 
(range 13–27 mmHg). Mean systolic and diastolic 
blood pressure values were 146.31 ± 14.45 mmHg and 
76.55 ± 10.87 mmHg, respectively. Mean heart rate was 
75.06 ± 10.95 bpm, and mean oxygen saturation levels were 
98.17% ± 1.31%.
After 4 weeks of treatment with Cosopt twice a day, mean 
IOP levels were 15.34 ± 2.27 mmHg (range 10–20 mmHg). 
Mean systolic and diastolic blood pressure values were 
142.96 ± 12.07 mmHg and 72.82 ± 10.44 mmHg, r  espectively. 
Mean heart rate was 71.62 ± 12.86 bpm, and mean oxygen 
saturation levels were 97.96% ± 1.20%.
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After another 4 weeks of treatment with Cosopt three 
times a day, mean IOP levels were 13.17 ± 1.81 mmHg (range 
9–17 mmHg). Mean systolic and diastolic blood pressure val-
ues were 145.51 ± 15.75 mmHg and 74.93 ± 12.46 mmHg, 
respectively. Mean heart rate was 71.20 ± 12.16 bpm, and 
mean oxygen saturation levels were 98.06% ± 0.96%. Data 
are presented in Table 1.
Treatment with Cosopt twice a day for 4 weeks resulted 
in a mean reduction of 5.71 ± 2.57 mmHg in IOP. This 
corresponds to a mean reduction of 25.90% ± 10.37% com-
pared with the baseline IOP values, which was statistically 
significant (P , 0.001).
Comparing IOP values after 4 weeks of treatment with 
Cosopt twice a day and after another 4 weeks of Cosopt 
three times a day revealed an additional reduction of IOP 
that varied between 0–6 mmHg. The higher dosage resulted 
in a mean additional reduction of 2.2 ± 1.58 mmHg in IOP, 
which corresponded with a change of 10.69% ± 7.49% of the 
baseline IOP values. This reduction was statistically signifi-
cant (P , 0.001). Data are presented in Figure 1.
Changes in systolic and diastolic blood pressure, heart 
rate, and oxygen saturation levels between all three time 
points were minimal and of no statistical significance. No 
patient complained of ocular surface irritation, and no patient 
suffered any systemic or local adverse effect that required 
cessation of Cosopt therapy.
Discussion
In this study, treatment with Cosopt twice a day caused a 
mean IOP reduction of 25.90% ± 10.37%, comparable to 
the results of previous studies of its efficacy.11,13,14,16,17,19–25 
This effect on IOP was expected, as most patients included 
in this study did not receive previous treatment. After 
another 4 weeks of treatment with an increased dosage of 
Cosopt three times a day, IOP had decreased by another 
2.2 ± 1.58 mmHg, corresponding to an additional reduction 
of 10.69% ± 7.49% of the baseline IOP value. The increased 
dosage was not associated with any significant systemic 
adverse effect or any change in blood pressure, heart rate, or 
oxygen saturation. It was also not associated with any local 
adverse effects or intolerability.
The strengths of this study include its prospective nature, 
exclusion of patients with any glaucoma other than POAG/
OHT, and its open label design emulating the real life clinical 
setting. Potential limitations of this study include its relatively 
small cohort size and short treatment duration. However, 
the purpose of the study was to assess the effect on IOP of 
increasing Cosopt dosage from twice to three times a day, and 
the study was designed for this comparison, which revealed 
statistically significant results.
This study is the first to evaluate Cosopt administered 
three times a day. Our results indicate that increasing Cosopt 
dosage from twice to three times a day is associated with 
increased efficacy in IOP reduction, with no change in its 
safety profile. The additional reduction in IOP was consid-
erable and statistically significant. This new finding is of 
clinical importance, as it has been demonstrated that every 
Table 1 Mean and standard deviation of IOP, systolic and diastolic blood pressure, heart rate, and oxygen saturation levels at baseline, 
after 4 weeks of treatment with Cosopt twice a day, and after 4 weeks of treatment with Cosopt 3 times a day
Time point IOP (mmHg) Systolic blood  
pressure (mmHg)
Diastolic blood 
pressure (mmHg)
Heart rate (bpm) Oxygen 
saturation 
levels (%)
Mean SD Mean SD Mean SD Mean SD Mean SD
Baseline 21.11 3.14 146.31 14.45 76.55 10.87 75.06 10.95 98.17 1.31
After 4 weeks  
of Cosopt × 2/day
15.34 2.27 142.96 12.07 72.82 10.44 71.62 12.86 97.96 1.20
After 4 weeks  
of Cosopt × 3/day
13.17 1.81 145.51 15.75 74.93 12.46 71.20 12.16 98.06 0.96
Note: Only the differences in IOP were of statistical significance (Bold).
Abbreviations: IOP, intraocular pressure; SD, standard deviation.
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Mean IOP
Baseline Cosopt 1 × 2/d Cosopt 1 × 3/d
Figure 1 Mean IOP values at baseline, after 4 weeks of treatment with Cosopt twice 
a day, and after another 4 weeks of treatment with Cosopt three times a day.
Note: Differences between time points were statistically significant.
Abbreviation: IOP, intraocular pressure.
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1 mmHg reduction in IOP is associated with approximately 
10% reduction in the risk of glaucoma progression.8 Since 
dorzolamide by itself is usually administered three times a 
day,16–17 it may be possible that it does not exert its full effect 
when given only twice a day as a component of Cosopt.
In conclusion, we found that Cosopt administered three 
times a day is more effective and as safe as when administered 
twice a day. Based on our results, we suggest that increasing 
Cosopt dosage to three times a day may be useful clinically 
in POAG/OHT patients in which a small yet significant 
additional reduction in IOP is required. Instead of changing 
or adding other antiglaucoma agents, this treatment may be 
a safe and simple way to achieve the target IOP. We also 
believe that increasing the dosage will not adversely affect 
patients’ compliance. It is possible that in POAG/OHT 
patients treated with Cosopt in which further IOP reduction 
is required, increasing the dosage to three times a day may 
be considered before other medications or surgery. Further 
large scale studies are required to corroborate our findings 
and establish their place in clinical practice.
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